In September 2004, Immpheron Inc was acquired by Canadian firm, Innexus Biotechnology Inc. Immpheron wors in close collaboration with InNexus, a biotechnology company focused on the development of its SuperAntibody Technology Platform; with emphasis on early corporate partnering with recognized pharmaceutical and biotechnology companies. Technical focus is on SuperAntibody Technology seeks to improve upon the therapeutic potency of the second generation of "humanized" monoclonal antibody products by increasing the binding to target antigen, enhancing antibody effector functions, and installing new properties into antibodies such as the ability to trigger apoptosis, or "cell suicide". Put simply, SuperAntibody Technology allows antibodies to achieve a higher level of therapeutic usefulness.ImmPheron is developing the next generation of therapeutic, monoclonal antibodies using the SuperAntibody Technology Formula.
